Taking it to the streets. Stockhouse.com: Taking it to the street
biOasis Technologies Inc.   BTI go to snapshot add to favorites
reply post threaded view
print report abuse
FOLD GSK & Fabry
KayakerBC2
12/19/2012 5:15:40 PM  |  | 405 reads  | Post #31933795
 

Amicus shares tank on PhIII failure for Fabry drug partnered with GlaxoSmithKline
December 19, 2012 | By Ryan McBride

Amicus Therapeutics ($FOLD) and its partner GlaxoSmithKline ($GSK) have stumbled in their journey to develop a new oral drug for a rare genetic disease. The companies reported late Wednesday that the first of two Phase III studies of Amigal--or migalastat HCL--failed to reach the primary efficacy goal in patients with the lysosomal storage disorder called Fabry disease....

....Amicus' share price fell fast in after-hours trading on Wednesday, trading down 50.65% to $2.85 or roughly half their closing value....

http://www.fiercebiotech.com/story/amicus-shares-tank-phiii-failure-fabry-drug-partnered-glaxosmithkline/2012-12-19

 

 

reply post threaded view
Company Showcase
 
View Sectors
 
 
 
Today's Feature  
View Now
 
Pacific North West Capital Corp.
Pacific North West Capital Corp. (TSX: PFN; OTCQX: PAWEF; Frankfurt: P7J) is a mineral exploration company focused on the discovery, exploration and development of PGM and nickel-copper sulphide deposits in geologically prospective regions in North America, particularly Canada. The Company's key asset is its 100% owned River Valley PGM Project in the Sudbury region of northern Ontario. The River Valley Project is one of North America's most advanced primary PGM deposits...